09 February 2026
09 February 2026
VERITAS involved 400 patients at 34 sites across Europe, Canada, and the US.
The trial showed fenebrutinib reduced disability progression risk by 12% compared to Ocrevus, the only approved PPMS treatment.
The San Diego facility forms part of the company’s $23bn US investment plan.
Eyas Medical Imaging is currently scaling up operations with plans to commercialise the system in the US later this year.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
